IDT Biologika Establishes New Corporation in the United States

03-Jun-2009 - USA

IDT Biologika announced it has opened new offices outside Washington, DC in Herndon, VA to better serve pharmaceutical and biopharmaceutical customers in the United States. According to the company, the move comes in response to expanding business by IDT Biologika with multinational firms and increased demand for the company’s fully-integrated services in the U.S. market. IDT Biologika’s expanded footprint in the Unites States market coincides with the opening of new filling and packaging facilities in Germany this past January.

According to Dr. Ralf Pfirmann, CEO of IDT Biologika, the establishment of operations in the United States will allow the company to support its customers´ operations in the important U.S. drug market and to develop closer working relationships with firms in the region.

Other news from the department business & finance

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?

Last viewed contents

Evotec Extends Medicinal Chemistry Collaboration with Ono Pharmaceutical

Revolutionary new insights into blood vessel formation in cancer - Research opens new avenue for cancer therapy

Antisense Pharma Obtains IND for Clinical Studies in the USA - The American Department of Health, the FDA, agrees to the use of trabedersen for high-grade glioma (malignant brain tumor)

Novel antibiotics in the fight against antimicrobial resistance - SANTERO announces a €8 million Series A funding round led by Newton Biocapital

Novel antibiotics in the fight against antimicrobial resistance - SANTERO announces a €8 million Series A funding round led by Newton Biocapital

KÖTTERMANN finds an investor

Combination Therapy against Cancer - Synergistic anticancer therapy with two cell killer agent systems in one nanocapsule

Combination Therapy against Cancer - Synergistic anticancer therapy with two cell killer agent systems in one nanocapsule

QUANTRO Therapeutics receives important Austrian research funding to further develop its platform for the discovery of novel cancer therapies - Austrian Research Promotion Agency FFG awards funding to QUANTRO to accelerate the next development phase of the company's proprietary research platform

QUANTRO Therapeutics receives important Austrian research funding to further develop its platform for the discovery of novel cancer therapies - Austrian Research Promotion Agency FFG awards funding to QUANTRO to accelerate the next development phase of the company's proprietary research platform

Max-Planck-Institut für Entwicklungsbiologie - Tübingen, Germany

Cell Cultivated Leather - VitroLabs raises $46 million to build and scale the world's first pilot production of cell cultivated leather

Cell Cultivated Leather - VitroLabs raises $46 million to build and scale the world's first pilot production of cell cultivated leather

Summit's lead drug candidate enters phase II clinical trials - Candidate targets sialorrhoea, a symptom of Parkinson's disease

Novartis enters into agreement for exclusive US and Canadian rights to Fanapt, an FDA-approved oral therapy for schizophrenia

UK start-up aims to advance pioneering NK cell therapy - NK:IO raises £1.2M, bringing total Seed funding to £5.1M

UK start-up aims to advance pioneering NK cell therapy - NK:IO raises £1.2M, bringing total Seed funding to £5.1M